Ignite Creation Date:
2025-12-24 @ 9:44 PM
Ignite Modification Date:
2026-01-03 @ 5:08 PM
Study NCT ID:
NCT03409432
Status:
COMPLETED
Last Update Posted:
2025-07-25
First Post:
2018-01-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
Sponsor:
John Reneau
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Lymphomatoid Papulosis | View |
| None | Primary Cutaneous Anaplastic Large Cell Lymphoma | View |
| None | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
| None | Recurrent T-Cell Non-Hodgkin Lymphoma | View |
| None | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
| None | Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
| None | Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
| None | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
| None | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
Keywords: